Adalimumab Found Effective, Safe in Psoriasis Subgroups

Improvement in psoriasis severity scores observed without differences in serious adverse event risk

MONDAY, Aug. 23 (HealthDay News) -- Adalimumab is consistently efficacious in the treatment of moderate to severe psoriasis across patient subgroups, and there are no significant differences in the risk of serious adverse events between adalimumab- and placebo-treated patients across weight categories, according to a post hoc analysis of REVEAL trial data in the September issue of the Journal of the American Academy of Dermatology.

Alan Menter, M.D., of the Baylor Psoriasis Research Institute in Dallas, and colleagues analyzed data on 1,212 patients from the REVEAL trial to determine efficacy and safety for subgroups defined by age, sex, race, baseline weight, body mass index (BMI), disease duration, severity, prior treatments, and comorbidities. The primary study end point was the percentage of patients achieving 75 percent or more improvement in the Psoriasis Area and Severity Index (PASI) score by 16 weeks.

The researchers found that consistent target PASI improvement was achieved in patient subgroups, though patients in the higher BMI and weight categories had somewhat reduced responses. There were no significant differences in serious adverse events between adalimumab- and placebo-treated patients for those with comorbidities at baseline or across weight categories. The most influential factors for mean percentage change in PASI score were treatment received, weight, and age.

"Subgroup analyses of REVEAL showed that although adalimumab demonstrated considerable efficacy in the treatment of patients with moderate to severe psoriasis, patients of greater weight and obese BMI experienced only modestly lower PASI 75 score responses at week 16 compared with patients of lesser weight and BMI," the authors write.

Abbott Laboratories provided funding for the manuscript, and study authors disclosed financial ties to Abbott and other pharmaceutical and medical device companies.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing